Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.49 |
| ▸ | GCGR | P47871 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7496200 | 0.83 | MAPK14 (0.58) | TDO2MAPK14GCGRRPS6KA3 | |
| SCHEMBL8836686 | 0.79 | MAPK14 (0.47) | MAPK14GCGRRAB9ANPC1RPS6KA3 | |
| SCHEMBL27765844 | 0.75 | NPC1 (0.47) | TDO2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL196861 | 0.72 | GCGR (0.67) | MAPK14GCGRRAB9ASMN1; SMN2MAPT | |
| SCHEMBL28279885 | 0.71 | RPS6KA3 (0.63) | TDO2MAPK14GCGRRAB9ASMN1; SMN2 | |
| SCHEMBL739660 | 0.71 | TDO2 (0.61) | TDO2MAPTLMNA | |
| SCHEMBL20507154 | 0.71 | TDO2 (0.47) | TDO2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL17532587 | 0.71 | TDO2 (1.00) | TDO2RAB9ANPC1NOTUMKDM4E | |
| SCHEMBL1168500 | 0.70 | MEN1 (0.47) | MAPK14GCGRRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1167381 | 0.70 | GAK (0.50) | SMN1; SMN2NPC1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1500657-B1 | Substituted pyrazoles as P38 kinase inhibitors | SEARLE LLC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-7153959-B2 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1682143-A2 | COMBINATIONS COMPRISING AN HSP90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | Pharmacia Corporation (US) | 2006-07-26 | — | — | EP | disclosed |
| US-7071198-B1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-6979686-B1 | Substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION (US) | 2005-12-27 | — | — | US | disclosed |
| WO-2005044194-A2 | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005041879-A2 | COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| EP-1500657-A1 | Substituted pyrazoles as P38 kinase inhibitors | G.D. Searle LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1144403-B1 | SUBSTITUTED PYRAZOLES AS P38 KINASE INHIBITORS | SEARLE LLC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | disclosed |
| US-6617324-B1 | Phenyl, cyclohexyl and pyridinyl or pyrimidinyl-substituted | G. D. SEARLE & COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6525059-B1 | Mitogen-activated protein kinases (MAP); | G. D. SEARLE & COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6514977-B1 | For treating p38 kinase mediated disorders | G.D. SEARLE & COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-6423713-B1 | Substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & COMPANY | 2002-07-23 | — | — | US | disclosed |
| CN-1342157-A | Substituted pyrazoles ASP38 kinase inhibitors | SEARLE & CO (US) | 2002-03-27 | — | — | CN | disclosed |
| EP-1144403-A1 | SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000031063-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | MAPK1, IL1R1, TNF | TDO2 1771/4885MAPK14 12/4885GCGR 1387/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | TDO2 2283/4885MAPK14 7/4885GCGR 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.